Scenario analysis for OAI units warning letter partly priced in The USFDA has classified three of Aurobindo Pharma's (ARBP) facilities API units 1 & 9 and intermediate unit 11 under OAI (official action indicated). These units were inspected in Feb'19 and received a total of 14 observations. Common 483s were around a lack of root cause analysis and production equipment validation. While existing sales won't be hit, we believe resolution at these sites will be key to future growth. In the worst case (WL), there could...